Immunogenicity and pre-clinical efficacy of an OMV-based SARS-CoV-2 vaccine

Mostrar otras versiones (1)

The vaccination campaign against SARS-CoV-2 relies on the world-wide availability of effective vaccines, with a potential need of 20 billion vaccine doses to fully vaccinate the world population. To reach this goal, the manufacturing and logistic processes should be affordable to all countries, irre...

Descripción completa

Detalles Bibliográficos
Autores principales: Grandi, Alberto, Tomasi, Michele, Ullah, Irfan, Bertelli, Cinzia, Vanzo, Teresa, Accordini, Silvia, Gagliardi, Assunta, Zanella, Ilaria, Benedet, Mattia, Corbellari, Riccardo, Lascio, Gabriele Di, Tamburini, Silvia, Caproni, Elena, Croia, Lorenzo, Ravà, Micol, Fumagalli, Valeria, Lucia, Pietro Di, Marotta, Davide, Sala, Eleonora, Iannacone, Matteo, Kumar, Priti, Mothes, Walther, Uchil, Pradeep D., Cherepanov, Peter, Bolognesi, Martino, Pizzato, Massimo, Grandi, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246226/
https://www.ncbi.nlm.nih.gov/pubmed/37292970
http://dx.doi.org/10.21203/rs.3.rs-2788726/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246226/
https://www.ncbi.nlm.nih.gov/pubmed/37292970
http://dx.doi.org/10.21203/rs.3.rs-2788726/v1

Ejemplares similares